Literature DB >> 18245665

A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor.

Lisa Gallinaro1, Maria Grazia Cattini, Maryta Sztukowska, Roberto Padrini, Francesca Sartorello, Elena Pontara, Antonella Bertomoro, Viviana Daidone, Antonio Pagnan, Alessandra Casonato.   

Abstract

ABO blood groups greatly influence circulating von Willebrand factor (VWF) levels, and O group subjects have lower VWF values. In this study, we investigated whether ABO groups affect VWF survival by monitoring the post-DDAVP (1-desamino-8-d arginine vasopressin) time courses of VWF antigen (VWF:Ag), VWF collagen binding (VWF:CB), and factor VIII (FVIII) in 47 healthy subjects (28 O and 19 non-O blood groups). The elimination half-life (T1/2el) of VWF was found significantly shorter in O than in non-O subjects (10.0+/-0.8 hours vs 25.5+/-5.3 hours, respectively; P<.01), as was the T1/2el of VWF:CB (7.9+/-0.5 hours vs 20.9+/-4.5 hours; P<.01). A direct linear correlation was found between basal VWF:Ag and T1/2el, subjects with higher VWF levels having longer-surviving VWF. ABO blood groups appeared to strongly influence VWF clearance, but not its synthesis or release from endothelial cells. The VWF propeptide to VWF:Ag ratio, useful for predicting an increased VWF clearance, was found significantly higher in O than in non-O individuals (1.6+/-0.1 vs 1.2+/-0.5, P<.001), with values that correlated inversely with T1/2el (P<.001). Based on these findings, we conclude that the lower VWF values in O group individuals is attributable to a shorter VWF survival and circulating VWF values are strongly influenced by its half-life.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245665     DOI: 10.1182/blood-2007-11-122945

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  87 in total

1.  ABO blood group is associated with peripheral arterial disease in African Americans: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Mindy M Pike; Nicholas B Larson; Christina L Wassel; Kevin P Cohoon; Michael Y Tsai; James S Pankow; Naomi Q Hanson; Paul A Decker; Cecilia Berardi; Kristine S Alexander; Mary Cushman; Neil A Zakai; Suzette J Bielinski
Journal:  Thromb Res       Date:  2017-02-24       Impact factor: 3.944

2.  Race, ABO blood group, and venous thromboembolism risk: not black and white.

Authors:  Chunhui Fang; Hillel W Cohen; Henny H Billett
Journal:  Transfusion       Date:  2012-04-27       Impact factor: 3.157

3.  Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium.

Authors:  Brian M Wolpin; Peter Kraft; Mousheng Xu; Emily Steplowski; Martin L Olsson; Alan A Arslan; H Bas Bueno-de-Mesquita; Myron Gross; Kathy Helzlsouer; Eric J Jacobs; Andrea LaCroix; Gloria Petersen; Rachael Z Stolzenberg-Solomon; Wei Zheng; Demetrius Albanes; Naomi E Allen; Laufey Amundadottir; Melissa A Austin; Marie-Christine Boutron-Ruault; Julie E Buring; Federico Canzian; Stephen J Chanock; J Michael Gaziano; Edward L Giovannucci; Göran Hallmans; Susan E Hankinson; Robert N Hoover; David J Hunter; Amy Hutchinson; Kevin B Jacobs; Charles Kooperberg; Julie B Mendelsohn; Dominique S Michaud; Kim Overvad; Alpa V Patel; Maria-José Sanchéz; Leah Sansbury; Xiao-Ou Shu; Nadia Slimani; Geoffrey S Tobias; Dimitrios Trichopoulos; Paolo Vineis; Kala Visvanathan; Jarmo Virtamo; Jean Wactawski-Wende; Joanne Watters; Kai Yu; Anne Zeleniuch-Jacquotte; Patricia Hartge; Charles S Fuchs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-22       Impact factor: 4.254

4.  Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.

Authors:  A B Ozel; B McGee; D Siemieniak; P M Jacobi; S L Haberichter; L C Brody; J L Mills; A M Molloy; D Ginsburg; J Z Li; K C Desch
Journal:  J Thromb Haemost       Date:  2016-08-19       Impact factor: 5.824

Review 5.  Laboratory testing for von Willebrand disease: toward a mechanism-based classification.

Authors:  Richard Torres; Yuri Fedoriw
Journal:  Clin Lab Med       Date:  2009-06       Impact factor: 1.935

Review 6.  ABO Blood Group as a Model for Platelet Glycan Modification in Arterial Thrombosis.

Authors:  Ming Zhong; Hanrui Zhang; John P Reilly; Jason D Chrisitie; Mayumi Ishihara; Tadahiro Kumagai; Parastoo Azadi; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-04       Impact factor: 8.311

7.  Impact of sickle cell trait on the thrombotic risk associated with non-O blood groups in northern Nigeria.

Authors:  Sagir G Ahmed; Modu B Kagu; Umma A Ibrahim; Audu A Bukar
Journal:  Blood Transfus       Date:  2015-05-27       Impact factor: 3.443

8.  ABO blood group in primary antiphospholipid syndrome: influence in the site of thrombosis?

Authors:  Natália Mastantuono Nascimento; Sergio Paulo Bydlowski; Rosangela Paula Silva Soares; Danieli Castro Oliveira de Andrade; Eloísa Bonfá; Luciana Parente Costa Seguro; Eduardo Ferreira Borba
Journal:  J Thromb Thrombolysis       Date:  2015-10       Impact factor: 2.300

Review 9.  von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.

Authors:  Paula D James; David Lillicrap
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

10.  The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels.

Authors:  Natalia Rydz; Laura L Swystun; Colleen Notley; Andrew D Paterson; J Jacob Riches; Kate Sponagle; Boonchai Boonyawat; Robert R Montgomery; Paula D James; David Lillicrap
Journal:  Blood       Date:  2013-03-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.